Algorithm-driven treatment for bipolar disorder in Korea: Clinical feasibility, efficacy, and safety

References

• Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. Expert consensus guideline series: medication treatment of bipolar disorder. Postgrad Med Special Report 2000; 2000: 1–104
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(Suppl 4):1–50.
   Web of Science ®Google Scholar
• Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870–86
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721–39
   PubMed Web of Science ®Google Scholar
• Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, et al. Texas medication algorithm project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry 2001; 62: 439–47
   PubMed Web of Science ®Google Scholar
• Suppes T, Rush AJ, Dennehy EB, Crismon ML, Kashner TM, Toprac MG, et al. Texas Medication Algorithm Project. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry 2003; 64: 370–82
   PubMed Web of Science ®Google Scholar
• Olfson M, Goldman HH. Psychiatric outpatient practice: patterns and policies. Am J Psychiatry 1992; 149: 1492–98
   PubMed Web of Science ®Google Scholar
• Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20: 163–8
   PubMed Web of Science ®Google Scholar
• Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006; 57: 133–6
   PubMed Web of Science ®Google Scholar
• The executive committee of the Korean medication algorithm project for bipolar disorder. Korean medication algorithm for bipolar disorder. Seoul: Jungang Moonhwa; 2002.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Young R, Biggs J, Meyer D. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429–35
   PubMed Web of Science ®Google Scholar
• Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76–338. National Institute of Mental Health, Rockville, MD 1976
   Google Scholar
• First MB. GAF report for the Global Assessment of Functioning Scale, window version: User's Manual. Multi Health System Inc, Toronto 1996
   Google Scholar
• Lingjarde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 334(Suppl)1–100
   Google Scholar
• Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G, Collings P. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practics. Aust NZ J Ment Health Nurs 2000; 9: 166–76
   PubMedGoogle Scholar
• Levine J, Chengappa KN, Brar JS, Gershon S, Yablonsky E, Stapf D, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120–30
   PubMed Web of Science ®Google Scholar
• Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64: 680–90
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006; 57: 660–5
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004; 4(6 Suppl 2)S17–25
   PubMedGoogle Scholar
• Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006; 20: 29–42
   PubMed Web of Science ®Google Scholar
• Bahk WM, Lee KU, Lee WH, Park YJ, Chae JH, Jun TY, et al. A trend of drug use in inpatients with bipolar disorder: a 4-year naturalistic study in one hospital. Korean J Psychopharmacol 2004; 15: 37–43
   Google Scholar
• Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198–214
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr. Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61(Suppl 8)52–61
   PubMed Web of Science ®Google Scholar
• Sachs G, Grossman F, Ghaemi S, Okamoto A, Bowden C. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146–54
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa K, Suppes T, Zarate CA, Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62–9
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24: 599–606
   PubMed Web of Science ®Google Scholar
• Keck P, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–8
   PubMed Web of Science ®Google Scholar
• Jon DI, Kim KR, Lee E, Son SJ. Re-evaluation of bipolar patients hospitalized for manic episode: possibility of diagnosing as a mixed episode. J Korean Neuropsychiatr Assoc 2006; 45: 337–42
   Google Scholar